Hua is a leading, clinical stage innovative drug development company in China focused on novel therapies for the treatment of diabetes. Founded by an experienced group of entrepreneurs and international investment firms, Hua advanced a first-in-class oral drug for the treatment of Type 2 Diabetes into NDA enabling stage and started 2 Phase 3 trials in China for drug naive and metformin treated T2D patients. The company also has initiated product life-cycle management studies of this novel diabetes drug, and advanced knowledge in personalized diabetes care. Hua's strategy is to leverage the cost-efficient and high-quality drug development capabilities available in China, while working very closely with disease experts in China and rest of world to advance diabetes care solutions for global patients.
Hua Medicine (“Hua” or the “Company”, Stock Code: 2552.HK), as a pre-revenue drug development company, today announced its interim results for the six months ended June 30, 2019 (the “Review Period”).
At last week’s American Diabetes Association’s 79th Scientific Sessions, Hua Medicine, a Shanghai-based drug development company focused on developing a global first-in-class oral drug for the treatment of Type 2 diabetes
Copyright © 2019 Hua Medicine, All Rights Reserved沪ICP备14036654号